Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study

IF 3.7 4区医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2025-03-26 DOI:10.1155/dth/7529636

Tiago Torres, Antonio Martorell, Paulo Leal Filipe, Caridad Soria, Fernando Mota, José Pardo, Miquel Ribera, Ricardo Ruiz-Villaverde

{"title":"Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study","authors":"Tiago Torres, Antonio Martorell, Paulo Leal Filipe, Caridad Soria, Fernando Mota, José Pardo, Miquel Ribera, Ricardo Ruiz-Villaverde","doi":"10.1155/dth/7529636","DOIUrl":null,"url":null,"abstract":"<div>\n Background and Aim: Quality of life (QoL) of psoriasis patients treated with calcipotriol/betamethasone dipropionate (Cal/BD) foam has not been thoroughly evaluated in real-world settings. This study evaluated the change in plaque psoriasis patients’ QoL after 4 weeks of first treatment with Cal/BD foam and after 6 months under daily practice conditions.\n Methods: A prospective, noninterventional study evaluated QoL, treatment adherence, satisfaction, and efficacy through the dermatology life quality index (DLQI), the Morisky-Green scale, the treatment satisfaction questionnaire for medication (TSQM-9), and the change in the body surface area (BSA) with plaque psoriasis, among others.\n Results: A total of 172 adult patients with plaque psoriasis were included. After 4 weeks of treatment, 53.5% of patients had a DLQI score ≤ 1. Mean absolute change in the DLQI score from baseline was −4.2 after 4 weeks of treatment and −4.0 after the 6-month follow-up (p < 0.0001). Improvement in the BSA was statistically significant after the first treatment period and after the 6-month follow-up with a mean reduction of 2.4% and 2.6%, respectively (p < 0.0001). Mean absolute change in global satisfaction between the end of the 4-week treatment period and the 6-month follow-up was −4.3 (p = 0.0049). In total, 41% of patients were compliant after the first treatment period, and 55.3% were moderately compliant. Higher patient treatment satisfaction was moderately correlated with lower DLQI scores after 4 weeks (r = −0.527; p < 0.0001). Statistically significant differences between DLQI groups were found in the BSA: patients with DLQI ≤ 1 after 4 weeks of treatment had a lower BSA than patients with DLQI > 1 (1.3 ± 1.8 vs. 2.8 ± 2.7, respectively; p < 0.0001).\n Conclusion: After 4 weeks of treatment, daily use of Cal/BD foam in plaque psoriasis patients resulted in an improvement in QoL that was related to an improvement in both satisfaction and efficacy.\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7529636","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/7529636","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aim: Quality of life (QoL) of psoriasis patients treated with calcipotriol/betamethasone dipropionate (Cal/BD) foam has not been thoroughly evaluated in real-world settings. This study evaluated the change in plaque psoriasis patients’ QoL after 4 weeks of first treatment with Cal/BD foam and after 6 months under daily practice conditions.

Methods: A prospective, noninterventional study evaluated QoL, treatment adherence, satisfaction, and efficacy through the dermatology life quality index (DLQI), the Morisky-Green scale, the treatment satisfaction questionnaire for medication (TSQM-9), and the change in the body surface area (BSA) with plaque psoriasis, among others.

Results: A total of 172 adult patients with plaque psoriasis were included. After 4 weeks of treatment, 53.5% of patients had a DLQI score ≤ 1. Mean absolute change in the DLQI score from baseline was −4.2 after 4 weeks of treatment and −4.0 after the 6-month follow-up (p < 0.0001). Improvement in the BSA was statistically significant after the first treatment period and after the 6-month follow-up with a mean reduction of 2.4% and 2.6%, respectively (p < 0.0001). Mean absolute change in global satisfaction between the end of the 4-week treatment period and the 6-month follow-up was −4.3 (p = 0.0049). In total, 41% of patients were compliant after the first treatment period, and 55.3% were moderately compliant. Higher patient treatment satisfaction was moderately correlated with lower DLQI scores after 4 weeks (r = −0.527; p < 0.0001). Statistically significant differences between DLQI groups were found in the BSA: patients with DLQI ≤ 1 after 4 weeks of treatment had a lower BSA than patients with DLQI > 1 (1.3 ± 1.8 vs. 2.8 ± 2.7, respectively; p < 0.0001).

Conclusion: After 4 weeks of treatment, daily use of Cal/BD foam in plaque psoriasis patients resulted in an improvement in QoL that was related to an improvement in both satisfaction and efficacy.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

IF 9.2 2区医学ACS Biomaterials Science & EngineeringPub Date : 2021-07-01 DOI: 10.1111/jdv.17211

D Rigopoulos, E Lazaridou, E Papadavid, S Georgiou, V Chasapi, K Sfaelos, G Cheliotis, D Ioannides

Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study

IF 3.6 4区医学Dermatologic TherapyPub Date : 2021-08-01 DOI: 10.1111/dth.15077

Anna Campanati, Laura Atzori, Concetta Potenza, Giovanni Damiani, Luca Bianchi, Monica Corazza, Rossana Tiberio, Francesca Prignano, Giuseppe Argenziano, Maria Concetta Fargnoli, Luca Stingeni, Annamaria Mazzotta, Ornella De Pità, Carlo Mazzatenta, Claudio Feliciani, Massimo Donini, Annamaria Offidani, Ketty Peris, LION study group

Real-life self-assessment of pruritus relief with a combination of calcipotriol/betamethasone dipropionate foam in patients with plaque psoriasis

IF 0 JEADV clinical practicePub Date : 2022-08-27 DOI: 10.1002/jvc2.45

Laurent Misery, Jessica Gonnet, Nadine Mackenzie, Nathalie Beneton, Bruno Halioua

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.